However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial 

Positive signals from early-phase studies suggest that newer molecular technologies may help to disclose the promises of T-cell therapies in different settings

Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease 

Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time 

In the NICHE-3 study, all patients achieved a pathological response  

Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas 

Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease

Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule 

Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma 

Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo